Centiva Capital’s Viking Therapeutics VKTX Stock Holding History

Centiva Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$431K	Buy	13,258 +758	+6%	+$24.4K	﹤0.01%	906
2025 Q4	$440K	Buy	+12,500	New	+$443K	﹤0.01%	748
2025 Q3	–	Sell	-7,500	Closed	-$224K	–	1885
2025 Q2	$199K	Buy	+7,500	New	+$197K	﹤0.01%	1344
2024 Q3	–	Sell	-67,633	Closed	-$3.59M	–	2631
2024 Q2	$3.59M	Buy	+67,633	New	+$4.43M	0.06%	221
2022 Q4	–	Sell	-10,840	Closed	-$29K	–	1647
2022 Q3	$29K	Buy	+10,840	New	+$35.5K	﹤0.01%	1369

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Centiva Capital's VKTX Position: Q1 2026 in Review

Centiva Capital increased its Viking Therapeutics (VKTX) stake by 6.1% in Q1 2026, buying an estimated $24.4K and bringing the position to 13,258 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #906.

Centiva Capital first reported a position in VKTX in Q3 2022 and has held it in 5 quarters since. The position peaked at $3.59M in Q2 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Centiva Capital held 13,258 shares of Viking Therapeutics worth $431K as of Q1 2026.
Centiva Capital bought 758 Viking Therapeutics shares in Q1 2026, an estimated $24.4K.
Viking Therapeutics made up ﹤0.01% of Centiva Capital's portfolio in Q1 2026, its #906 holding.
Centiva Capital first reported a position in Viking Therapeutics in Q3 2022 and has held it in 5 quarters since.
Centiva Capital's Viking Therapeutics position peaked at $3.59M in Q2 2024.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.